Report
Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients
| العنوان: | Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients |
|---|---|
| المصدر: | A Randomized, Open-label, PK and Safety Study to Evaluate the Relative Exposure and Safety of a New Formulation vs the Approved Formulation of a Single 1200 mg IV Dose of ORBACTIV® (Oritavancin) in Subjects Being Treated for ABSSSI |
| قاعدة البيانات: | ClinicalTrials.gov |
| الوصف غير متاح. |